-

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-itci/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
Lewis S. Kahn
Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Industry:

Kahn Swick & Foti, LLC

NASDAQ:ITCI
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
Lewis S. Kahn
Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

More News From Kahn Swick & Foti, LLC

Activision Blizzard 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Activision Blizzard Inc. - ATVI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against Activision Blizzard Inc. (“Activision” or the "Company") (NasdaqGM: ATVI), if they sold Activision common stock between January 18, 2022 and October 13, 2023, inclusive (the “Class Period”) (excluding those tha...

Avanos Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avanos Medical, Inc. - AVNS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners. Under the terms of the proposed transaction, shareholders of Avanos will receive $25.00 in cash for each share of Avanos that they own. KSF is seeking to determine whether this consideration and the process that led to i...

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t...
Back to Newsroom